Our Vision to Cure is being achieved by funding the best research. A newly developed antibody, CSL362, could lead to a new targeted approach to the treatment of acute myeloid leukaemia (AML). Collaborative research published today, defines how CSL362 binds to AML cancer cells and the antibody then recruits the body’s own immune system to kill the cancer cells, potentially preventing the relapse of AML. We are pleased to have funded Dr Sophie Broughton of St Vincent’s Institute of Medical Research (where the atomic structure of CSL362 was discovered). Dr Broughton is mid-way through a Postdoctoral Fellowship (annual funding of $100,000, 2013-2015).
Posted on: Fri, 18 Jul 2014 08:00:00 +0000